What Is CagriSema? Cagrilintide + Semaglutide Research Guide 2026
CagriSema is Novo Nordisk’s investigational fixed-ratio co-formulation combining cagrilintide (a long-acting amylin analog; CAS 2219415-09-3) and semaglutide (GLP-1 receptor agonist; CAS 910463-68-2), currently in Phase 3 evaluation across the REDEFINE clinical program. Unlike retatrutide’s single-molecule triple agonism, CagriSema achieves dual-pathway receptor engagement by combining two distinct peptide drugs — each optimized for its own receptor family. The rationale is simple: GLP-1R and amylin receptors signal through different neural circuits and different downstream mechanisms, and activating both produces metabolic effects neither compound achieves alone.
What Is Cagrilintide? (The Amylin Component)
Cagrilintide is a next-generation long-acting amylin analog engineered by Novo Nordisk to replicate the metabolic activity of endogenous amylin (IAPP — islet amyloid polypeptide) while achieving a ~7-day half-life. Native amylin has a plasma half-life of minutes; cagrilintide achieves extended duration through the same C18 fatty diacid albumin-binding technology used in semaglutide — effectively applying the half-life extension strategy that revolutionized GLP-1 agonism to the amylin receptor class.
Cagrilintide activates all three amylin receptor subtypes — AMY1R (CTR + RAMP1), AMY2R (CTR + RAMP2), and AMY3R (CTR + RAMP3) — as well as the calcitonin receptor (CTR) directly. These receptors are expressed in the area postrema, lateral parabrachial nucleus, and central amygdala — regions with distinct appetite-regulatory connectivity that GLP-1R agonists engage far more weakly. This neuroanatomical distinction is the mechanistic core of the CagriSema rationale.
What Is Semaglutide? (The GLP-1 Component)
Semaglutide needs less introduction: it is the GLP-1 receptor agonist active in FDA-approved Ozempic (T2D, weekly injection) and Wegovy (chronic weight management). With 94% homology to native GLP-1 and a ~7-day half-life from its C18 fatty diacid albumin chain, semaglutide is the most clinically validated GLP-1R agonist available. In the CagriSema combination, semaglutide provides robust GLP-1R signaling in the arcuate nucleus, nucleus tractus solitarius, and paraventricular nucleus — the hypothalamic core of appetite regulation.
REDEFINE: What the Phase 2 and Phase 3 Data Shows
A landmark Phase 2 study published in The Lancet (2021) compared four arms: cagrilintide alone, semaglutide alone, CagriSema combination, and placebo over 20 weeks. The combination arm showed greater reductions in body weight endpoints than either monotherapy at equivalent doses — the first clinical evidence that amylin + GLP-1 dual-pathway engagement is synergistic rather than simply additive.
Phase 3 REDEFINE-1 (2.4 mg cagrilintide + 2.4 mg semaglutide, N = 3,400+) reported results in 2025 showing approximately 22–25% mean body weight reduction at 68 weeks — outcomes placing CagriSema among the most effective weight management compounds in clinical development, comparable to retatrutide’s Phase 2 profile. REDEFINE-2, REDEFINE-3 (T2D), and REDEFINE-4 (cardiovascular) are the companion Phase 3 trials rounding out the CagriSema clinical program.
Why the Dual-Pathway Strategy Works: Neuroscience Behind CagriSema
The key insight driving CagriSema is that satiety is not a single signal from a single brain region. GLP-1R agonism strongly activates the hypothalamic ARC-PVN axis and the brainstem NTS — well-characterized pathways. Amylin receptor activation targets the area postrema and lateral parabrachial nucleus, which project to the central amygdala and bed nucleus of the stria terminalis — circuits governing the aversive/hedonic valence of feeding behavior. By recruiting both neural systems simultaneously, CagriSema creates a more complete satiety signal architecture than either compound alone can produce.
Frequently Asked Questions — CagriSema
Is CagriSema the same as semaglutide?
No. Semaglutide (GLP-1R agonist) is one component of CagriSema. The other component is cagrilintide, a long-acting amylin analog targeting AMY1R, AMY2R, AMY3R, and CTR — receptors that semaglutide does not activate. CagriSema is a dual-compound combination, not a modified version of semaglutide.
How does CagriSema compare to retatrutide?
Both target the GLP-1R but through different strategies. Retatrutide (GLP-3) adds GIPR and GCGR activation to GLP-1R in a single molecule. CagriSema adds amylin receptor activation to GLP-1R in a two-compound combination. The receptor targets are entirely different — neither is a subset of the other.
Is CagriSema FDA-approved?
As of 2026, CagriSema is in Phase 3 clinical trials with no regulatory approval. Both components (cagrilintide and semaglutide) are available as research-grade peptides from Combat Research.
